Patents by Inventor Amy M. Beebe

Amy M. Beebe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEINS BINDING NKG2D, CD16, AND CEACAM5
    Publication number: 20240124607
    Abstract: Multi-specific binding proteins that bind NKG2D, CD16, and CEACAM5 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer
    Type: Application
    Filed: August 8, 2023
    Publication date: April 18, 2024
    Inventors: Amy M. Beebe, Laurence Fayadat-Dilman, Veronica M. Juan, Gregory P. Chang, Souvik Chattopadhyay, Ann F. Cheung, Asya Grinberg, Pyae P. Hein, Nicolai Wagtmann
  • DOSING REGIMEN OF ANTI-CD27 ANTIBODIES FOR TREATMENT OF CANCER
    Publication number: 20230192876
    Abstract: The present invention relates to methods of treating cancer by administering an anti-CD27 antibody as a monotherapy or as a part of a combination thereof.
    Type: Application
    Filed: October 29, 2020
    Publication date: June 22, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Elliot K. Chartash, Amy M. Beebe, Jason K. Cheung, Konstantin Dobrenkov, Claire H. Li, Richard Wnek
  • Modulation of tumor immunity
    Patent number: 10994008
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 4, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • ANTI-CD27 ANTIBODIES
    Publication number: 20200131272
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Anti-CD27 antibodies
    Patent number: 10556957
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: February 11, 2020
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • ANTI-CD27 ANTIBODIES
    Publication number: 20190300618
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: September 25, 2017
    Publication date: October 3, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Modulation of tumor immunity
    Patent number: 10188729
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • MODULATION OF TUMOR IMMUNITY
    Publication number: 20180207266
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Application
    Filed: March 20, 2018
    Publication date: July 26, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • ANTI-CD27 ANTIBODIES
    Publication number: 20180086841
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: September 25, 2017
    Publication date: March 29, 2018
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • MODULATION OF TUMOR IMMUNITY
    Publication number: 20160199487
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Danling Gu, Amy M. Beebe
  • Uses of mammalian cytokine; related reagents
    Publication number: 20080226654
    Abstract: Provided are methods of treatment for bone disorders related to bone deposition and resorption dysfunction. These bone disorders may be the result of inflammation, cancers, etc. Provided are methods of using agonists or antagonists of a cytokine molecule.
    Type: Application
    Filed: July 13, 2006
    Publication date: September 18, 2008
    Applicant: Schering Corporation
    Inventors: J. Fernando Bazan, Amy M. Beebe, Rene de Waal Malefyt, Daniel M. Gorman, Peter Kirk, Hirokazu Kurata, Donna Rennick
  • Uses of mammalian cytokine; related reagents
    Publication number: 20030082184
    Abstract: Provided are methods of treatment for bone disorders related to bone deposition and resorption dysfunction. These bone disorders may be the result of inflammation, cancers, etc. Provided are methods of using agonists or antagonists of a cytokine molecule.
    Type: Application
    Filed: August 6, 2002
    Publication date: May 1, 2003
    Inventors: J. Fernando Bazan, Amy M. Beebe, Rene de Waal Malefyt, Daniel M. Gorman, Peter Kirk, Hirokazu Kurata, Donna Rennick